Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine, cytarabine, and unrelated cord blood transplantation in older patients with AML in complete remission
ChiCTR-OPC-15006492Phase 3Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jul 2015
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of decitabine, cytarabine, umbilical cord blood stem cells, mercaptopurine, tretinoin and 1 more in acute myeloid leukemia (AML), sponsored by Ruijin Hospital. Primary endpoint: Disease-free survival. Planned start Jul 2015; status: not yet recruiting.
02
Drugs
decitabinecytarabineumbilical cord blood stem cellsmercaptopurinetretinoin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR-OPC-15006492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-15006492.